证券代码：688046 证券简称：药康生物 公告编号：2025-072 江苏集萃药康生物科技股份有限公司 关于股份回购实施结果暨股份变动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2024/10/31 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 回购方案实施期限 | 年 2024 10 | 10 | 月 | 29 | 日~2025 | 年 | 月 | 日 28 | | 预计回购金额 | 2,200万元~4,000万元 | | | | | | | | | 回购价格上限 | 18.00元/股 | | | | | | | | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 | | | | | | | | | | □用于转换公司可转债 | | | | | | | | | | □为维护公司价值及股东权益 | | | | | | | | | 实际回购股数 | 1,5 ...

Investment Rating - The report maintains an investment rating of "Outperform the Market - A" for the life sciences upstream sector [6]. Core Insights - The life sciences upstream sector is experiencing simultaneous domestic substitution and accelerated international expansion, with significant room for improvement in the localization rates of research reagents, consumables, and high-end scientific instruments [1][22]. - The demand side is improving due to favorable trends in innovative drug development and supportive national policies, with domestic innovative drug companies' overseas business development (BD) transactions expected to exceed $100 billion in 2025, nearly doubling from 2024 [2][25]. - The supply side is also gradually improving, with domestic life sciences companies achieving technological breakthroughs and expanding their business pipelines through both organic growth and acquisitions [2][29]. - Key companies are showing signs of performance improvement, with notable growth in revenue and net profit for firms like Baipusais and Aopumai [2][34]. Summary by Sections 1. Life Sciences Upstream Overview - The life sciences upstream includes research reagents, experimental consumables, instruments, and comprehensive services, playing a crucial role in various applications such as antibody drugs and gene therapy [9][10]. 1.1 Domestic Substitution and International Expansion - The localization rates for research reagents are around 10%, with high-end scientific instruments having an import rate of approximately 70.6% [22][23]. 1.2 Demand Side Improvement - The innovative drug sector is witnessing a recovery, with significant increases in overseas BD transactions, indicating a robust demand for life sciences products [25][27]. 1.3 Supply Side Enhancements - Domestic companies are making technological advancements, with key players like Aopumai and Baipusais expanding their product lines and market presence through acquisitions and internal development [29][30]. 1.4 Company Performance Trends - Companies such as Baipusais and Aopumai have reported substantial improvements in their financial performance, with Baipusais showing a 31% year-on-year revenue growth and Aopumai achieving a remarkable 402% increase in net profit [34]. 2. Recommended Stocks - Suggested stocks to watch include Baipusais, Aopumai, Aladdin, and others in the research reagent and scientific instrument sectors [2].

Investment Rating - The report maintains a "Recommended" rating for the company [1][6][10] Core Insights - The company reported a Q3 2025 revenue of 201 million yuan, representing a year-over-year increase of 18.56%, and a net profit of 39 million yuan, up 78.25% year-over-year [3][6] - The gross margin for Q3 2025 was 63.53%, an increase of 1.65 percentage points year-over-year, attributed to improved operational efficiency [6] - The company has made adjustments to its overseas team structure and is expanding its market presence, with a new base in San Diego set to enhance supply and response capabilities [6] - Future profit forecasts for 2025-2027 are set at 127 million, 158 million, and 197 million yuan respectively, indicating a positive outlook for growth [6] Financial Summary - Revenue projections for 2024, 2025, 2026, and 2027 are 687 million, 802 million, 939 million, and 1,108 million yuan respectively, with year-over-year growth rates of 10.4%, 16.7%, 17.1%, and 18.0% [5][8] - Net profit estimates for the same years are 110 million, 127 million, 158 million, and 197 million yuan, with year-over-year changes of -30.9%, 15.5%, 24.8%, and 24.6% [5][8] - The company’s net profit margin is projected to improve from 16.0% in 2024 to 17.8% in 2027 [8] Financial Ratios - The company's return on equity (ROE) is expected to increase from 5.1% in 2024 to 7.5% in 2027 [8] - The asset-liability ratio is projected to remain stable, with values of 17.0%, 15.9%, 16.5%, and 17.3% for 2024 to 2027 respectively [8] - The price-to-earnings (P/E) ratio is forecasted to decrease from 63.5 in 2024 to 35.4 in 2027, indicating potential valuation improvement [8]

Investment Rating - The report assigns a "Buy" rating for the stock of YaoKang Bio (688046) based on its performance and growth potential [11]. Core Insights - YaoKang Bio has shown a quarterly acceleration in performance, with a revenue of 576 million yuan for the first three quarters of 2025, representing a year-on-year growth of 12.92%. The net profit attributable to the parent company reached 110 million yuan, up 11.90% year-on-year, and the non-recurring net profit was 93 million yuan, reflecting a significant increase of 29.21% [1][2]. - The functional efficacy business is identified as a key driver of growth, with a revenue of 87.93 million yuan in the first half of 2025, marking a year-on-year increase of 23.69%. New orders have surged by over 40% year-on-year, indicating strong demand [2]. - The establishment of a wholly-owned subsidiary, NiuMai Bio, aims to cultivate a fully human antibody platform, which is expected to become a significant growth engine for the company. The subsidiary has completed comprehensive validation of various human antibody models and is actively engaged in innovative antibody research across multiple therapeutic areas [3]. Financial Performance Summary - For the fiscal years 2025 to 2027, the projected revenues are 790 million yuan, 950 million yuan, and 1.144 billion yuan, respectively, with corresponding net profits of 143 million yuan, 177 million yuan, and 221 million yuan. The earnings per share (EPS) are expected to be 0.35 yuan, 0.43 yuan, and 0.54 yuan, with price-to-earnings (P/E) ratios of 48.79, 39.49, and 31.57 [4][5].

证券代码：688046 证券简称：药康生物 公告编号：2025-071 江苏集萃药康生物科技股份有限公司 关于调整 2025 年半年度利润分配现金分红总额 的公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 具 体 内 容 详 见 公 司 于 2025 年 8 月 23 日 在 上 海 证 券 交 易 所 网 站 （www.sse.com.cn）披露的《关于公司 2025 年半年度利润分配预案的公告》（公 告编号：2025-056）。 二、调整原因 自 2025 年 6 月 30 日起至本公告披露日，公司通过上海证券交易所交易系统 以集中竞价交易方式回购公司股份 480,638 股。自 2025 年 6 月 30 日起至本公告 披露日，公司于 2025 年 10 月 27 日收到中国证券登记结算有限责任公司出具的 《证券过户登记确认书》，公司回购专用证券账户中所持有的 460,000 股公司股 票已于 2025 年 10 月 24 日非交易过户至"江苏集萃药康生物科技股份有限公司 －2025 年员工持股计划"证券 ...

根据《关于上市公司实施员工持股计划试点的指导意见》及《上海证券交易所 科创板上市公司自律监管指引第 1 号——规范运作》的相关规定，现将公司 2025 年 员工持股计划（以下简称"本员工持股计划"）的实施进展情况公告如下： 2025年员工持股计划预留份额共计327.52万份（对应公司A股普通股股票46.00 万股），根据参与公司 2025 年员工持股计划预留份额实际认购和最终缴款的审验结 果，公司 2025 年员工持股计划参与认购预留份额的员工为 12 人，共计认购本员工 持股计划份额 327.52 万份，每份份额为 1 元，共计缴纳认购资金 327.52 万元，对应 认购公司回购专用证券账户库存股 460,000 股。 证券代码：688046 证券简称：药康生物 公告编号：2025-070 江苏集萃药康生物科技股份有限公司 关于 2025 年员工持股计划 预留份额非交易过户完成的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 江苏集萃药康生物科技股份有限公司（以下简称"药康生物"或"公司"）于 2025 年 3 月 ...

Group 1: Gold Accumulation Business - Several banks have raised the minimum investment threshold for gold accumulation business to between 950 to 1200 yuan, an increase of 300 to 550 yuan compared to the beginning of the year [1] Group 2: Deposit Rate Adjustments - Multiple small and medium-sized banks have lowered deposit rates, leading to a phenomenon where long-term deposit rates are lower than short-term rates, with some banks showing that "three-year deposits yield less than one-year deposits" [2] - On October 20, Pingyang Pudong Development Bank announced adjustments to various deposit rates effective from October 21 [2] - Fujian Huatuo Bank and Shanghai Huarui Bank also announced reductions in their deposit rates, with the three-year fixed deposit rate dropping from 2.3% to 2.15% [2] Group 3: Capital Increase by Cambrian - Cambrian announced the completion of a capital increase, with 3,334,946 new shares registered on October 16 [4] - The largest allocation went to GF Fund, which received 1,010,900 shares, amounting to 1.208 billion yuan [4] - Other institutions, including Huatai-PineBridge Fund and Bosera Fund, received allocations ranging from 100,400 to 364,000 shares [4] Group 4: Investment Activity in Pharmaceutical Sector - Guo Lan's fund management has increased its stake in Yaokang Biotechnology, becoming the ninth largest shareholder with 5,162,200 shares as of the end of Q3 [5] - The fund managed by Guo Lan and Zhao Lei also appears among the top ten shareholders, holding 12,860,600 shares, an increase of 4,877,600 shares compared to the previous quarter [5] Group 5: Fund Risk Level Adjustments - Since September, nearly 20 fund companies have issued over 20 announcements regarding risk level adjustments for public funds, significantly higher than the previous monthly average [6][7] Group 6: Cross-Border ETF Premium Risks - Several fund companies, including Huaxia Fund and Hua'an Fund, have issued urgent risk warnings regarding high premium rates for cross-border ETFs, indicating potential significant losses for investors [8]

Investment Rating - The report maintains a "Positive" investment rating for the pharmaceutical and biotechnology industry [1] Core Insights - The report highlights significant advancements in innovative drugs, particularly in the context of recent clinical trial results presented at the 2025 ESMO conference, showcasing the potential for new treatment options in various cancer types [12][19] - The report emphasizes the emergence of domestic drugs that have achieved notable efficacy in treating conditions such as NSCLC and HER2-positive breast cancer, indicating a shift in the competitive landscape [13][17] Summary by Sections 1. New Drug Developments - **2L EGFR Mutant NSCLC**: The drug Lukanosumab (sac-TMT) is the first to demonstrate both overall survival (OS) and progression-free survival (PFS) benefits in patients with TKI-resistant NSCLC, with mPFS of 8.3 months compared to 4.3 months for chemotherapy [13][14] - **HER2 Positive Breast Cancer**: The drug Ruikang Trastuzumab shows longer mPFS of 30.6 months compared to 8.3 months for the chemotherapy combination, indicating a promising new option for patients [17][18] - **T-Bren for Breast Cancer**: Early data from the T-Bren trial shows a clinical overall response rate (cORR) of 82.2% in HER2-positive patients, with mPFS of 18.0 months [19][20] - **2L HER2 Positive Gastric Cancer**: Anniotuzumab combined with chemotherapy shows significant improvements in mPFS (7.1 months vs 2.7 months) and mOS (19.6 months vs 11.5 months), suggesting a potential shift in treatment paradigms [21][24] 2. Market Performance - The pharmaceutical and biotechnology sector saw a 0.58% increase in October, underperforming the CSI 300 index by 2.67 percentage points, ranking 25th among 31 sub-industries [25][30] - The medical research outsourcing sector experienced the highest growth, up 5.47%, while other bioproduct sectors faced declines [30][34]

Core Insights - On October 23, 2023, brokerage firms provided target prices for listed companies, with significant increases noted for companies in the pet feed and communication equipment sectors, specifically Guibao Pet, StarNet RuiJie, and Weisheng Information, with target price increases of 61.09%, 50.73%, and 43.78% respectively [1][2]. Target Price Increases - Guibao Pet (301498) received a target price of 118.00 yuan, reflecting a target price increase of 61.09% from the latest closing price [2]. - StarNet RuiJie (002396) has a target price of 39.16 yuan, with a target price increase of 50.73% [2]. - Weisheng Information (688100) has a target price of 51.00 yuan, showing a target price increase of 43.78% [2]. - Other notable companies include China Unicom (600050) with a target price increase of 36.22% and Wens Foodstuff Group (300498) with an increase of 33.28% [2]. Brokerage Recommendations - A total of 59 listed companies received brokerage recommendations on October 23, with Tonghuashun (300033) receiving the highest number of recommendations at 5, followed by Guibao Pet with 4, and Meihua Biological (600873) with 3 [3][4]. - The sectors represented include software development, feed, and chemical products [4]. Rating Adjustments - On October 23, only one company, Huayou Cobalt (603799), had its rating upgraded from "Hold" to "Buy" by Huayuan Securities [5]. - This indicates a positive outlook for the energy metals sector [5]. First-Time Coverage - Nine companies received first-time coverage from brokerages on October 23, with notable mentions including Innovation New Materials (600361) rated "Buy" by Huayuan Securities, and YunTu Holdings (002539) and Meihua Biological (600873) both rated "Buy" by Global Fortune Financial [6]. - Other companies receiving first-time ratings include Babi Food (605338) and Shengquan Group (108850) [6].

Investment Rating - The report maintains a "Buy" rating for the company [6] Core Insights - The company's performance exceeded market expectations, with Q3 2025 revenue reaching 201 million yuan, a year-on-year increase of 18.56%, indicating a trend of accelerating growth compared to H1 2025 [2] - The overseas business contributed significantly to the company's performance, with Q3 2025 overseas revenue of 39 million yuan, a year-on-year increase of 63.97, showcasing the company's ability to adapt and grow in international markets [2] - The report predicts continued rapid growth for the company due to ongoing capacity expansion and a focus on both domestic and international market development [2] Financial Summary - For the fiscal years 2025 to 2027, the revenue forecast has been adjusted to 795 million yuan, 939 million yuan, and 1.11 billion yuan respectively, with corresponding EPS adjusted to 0.35 yuan, 0.42 yuan, and 0.51 yuan [3] - The projected PE ratios for 2025, 2026, and 2027 are 49, 40, and 33 times respectively, based on the closing price of 17.05 yuan per share on October 23, 2025 [3] - The financial summary indicates a revenue growth rate of 15.8% for 2025, with a net profit growth rate of 29.5% [5]